AstraZeneca shares fell nearly 9% as investors reacted to potential merger talks with Bristol Myers Squibb.
AstraZeneca shares dropped 8.9% following reports of potential merger talks with the US pharmaceutical group Bristol Myers Squibb. Sir Pascal Soriot, the chief executive of AstraZeneca, has led the company through a successful period, including the 2021 purchase of Alexion. However, the proposed $400bn mega-merger appears to be a high-risk financial adventure that may be out of character for the company's current strategy. Sir Pascal Soriot has historically favored smart licensing and partnerships over large corporate takeovers. While the merger would create a global oncology colossus, it would also bring significant debt and a complex regulatory approval process. Analysts suggest that AstraZeneca currently has a strong financial position and does not necessarily need complex financial engineering. Given the company's recent success in hitting revenue targets, many shareholders seem to prefer the current path over a risky transatlantic merger.